Abry Closes $780M Continuation Fund for Centauri Health

Abry Partners just bet another $780 million that it can squeeze more value out of Centauri Health Solutions — and found plenty of investors willing to agree.

The Boston-based private equity firm closed an oversubscribed continuation vehicle for the physician services platform on June 15, according to a company announcement. The deal, one of 2026's largest healthcare continuation funds, lets Abry extend its hold on Centauri while offering existing limited partners a chance to either cash out or roll forward into the new structure.

Centauri — a roll-up of specialty physician groups across dermatology, ophthalmology, and gastroenterology — has been in Abry's portfolio since 2019. The firm's decision to pursue a continuation vehicle rather than exit signals two things: Abry thinks there's meaningful upside left, and the secondary market has regained enough momentum to absorb large healthcare assets after a sluggish 2024-2025 period.

What makes this notable isn't just the size. It's the timing. Continuation vehicles fell sharply out of favor 18 months ago as rising rates and valuation disputes between GPs and LPs froze the market. That Abry not only executed this deal but oversubscribed it suggests the ice is thawing — at least for assets with defensible cash flow and clear runway.

Continuation vehicles exist to solve a specific problem: what to do when a portfolio company still has growth potential but the fund holding it is nearing the end of its life. Rather than sell into a soft market or rush an IPO that might undervalue the asset, sponsors create a new fund — the continuation vehicle — to buy the company from the old fund.

Existing LPs can choose to roll their stake into the new vehicle or take liquidity. New investors can come in at current valuation. The GP — in this case, Abry — retains control and resets the clock.

For Centauri, the math apparently still works. The platform has added dozens of physician practices since Abry's initial investment, building density in key metros and negotiating better payor contracts as scale increased. Dermatology and ophthalmology, two of Centauri's core specialties, remain fragmented — meaning there's still acquisition runway if the company can keep accessing capital.

But the decision also reflects market conditions. Healthcare services valuations compressed in 2024 as interest rates peaked and buyers pulled back. Selling Centauri into that environment would've likely meant accepting a lower multiple than Abry believed the asset deserved. The continuation vehicle lets them wait for a better exit window while still providing liquidity to LPs who want out now.

Abry didn't disclose the exact split between rollover equity and new capital, but continuation vehicle structures typically follow a pattern: some portion of the existing LP base rolls forward, new secondaries buyers provide fresh capital, and the GP often reinvests alongside.

The "oversubscribed" label matters. It means demand for the vehicle exceeded the target raise — a sign that institutional investors see Centauri as an attractive risk-adjusted bet even at today's valuation. That's not guaranteed in this market. Plenty of continuation vehicles in the past two years failed to close or repriced downward mid-process as LPs balked at GP valuations.

The $780 million figure places this among the upper tier of healthcare continuation vehicles closed in 2026. For context, the median healthcare CV in the trailing 12 months has been in the $300-500 million range, according to secondary market data. Larger deals — those above $700 million — have been rare, concentrated in only the most defensive subsectors: behavioral health, physician services, and specialty pharmacy.

Centauri likely sits in the middle band — significant LP rollover, but enough new capital to signal external validation of the valuation.

Abry didn't name the investors in the continuation vehicle, but the buyer profile is predictable. Secondaries funds — firms like Lexington Partners, Coller Capital, and HarbourVest — are the usual suspects in large continuation deals. These funds specialize in buying LP stakes at a discount or participating in CV structures where they get exposure to a single asset rather than a blind pool.

Centauri Health Solutions is a textbook private equity healthcare play: buy small independent physician practices, consolidate them under a single management platform, extract operational efficiencies, negotiate better reimbursement rates, then either sell to a larger platform or take public.

The model works — when it works — because small practices lack bargaining power with insurers and lack the infrastructure to maximize billing, scheduling, and supply chain efficiency. Bring them under a corporate umbrella, professionalize the back office, and margins improve.

But the model also has well-documented failure modes. Integration is expensive and slow. Physicians chafe under corporate oversight. Payor contracts don't always improve as much as the models predict. And regulatory risk is constant — states periodically crack down on private equity ownership of medical practices, particularly in specialties where patient volume incentives can conflict with care quality.

Centauri's focus on dermatology, ophthalmology, and gastroenterology is strategic. These specialties have high procedural volumes, predictable reimbursement, and lower regulatory scrutiny than, say, emergency medicine or pain management. Derm in particular has been a PE darling for a decade — Schweiger Dermatology, Advanced Dermatology and Cosmetic Surgery, and Forefront Dermatology all followed similar roll-up paths.

The question for Abry: is there enough white space left in these markets to justify another three to five years of growth capital, or has consolidation already pushed multiples and integration costs to the point where returns compress?

Centauri competes with a crowded field of PE-backed physician platforms. In dermatology alone, the major players include Advanced Dermatology and Cosmetic Surgery (Oak Hill Capital), Schweiger Dermatology (TSG Consumer Partners), Forefront Dermatology (sold to private equity multiple times before exiting to Oak Street Health's parent), and a dozen smaller regional aggregators.

Ophthalmology and GI have similar dynamics. EyeSouth Partners, Retina Consultants of America, and United Digestive all run the same operational model Centauri does. The edge comes down to execution speed, integration competence, and market timing.

Continuation vehicles fell sharply out of favor in late 2024 after a wave of LP backlash. The core complaint: GPs were using CVs to avoid taking a loss on struggling assets, effectively forcing LPs to either accept an unattractive rollover or sell at a steep discount.

The market froze. Deal volume in the secondaries market — including continuation vehicles — dropped 40% year-over-year in 2024, and pricing disputes became the norm rather than the exception. GPs wanted to value assets based on future potential; LPs wanted current market comps. Very few deals threaded that needle cleanly.

That Abry closed an oversubscribed vehicle suggests the standoff is easing, at least for high-quality assets. Healthcare services platforms with stable cash flow, recurring revenue, and clear growth vectors are finding buyers again. The discount rates may be higher than they were in 2021, but the market is functional.

The broader question: is this a signal that continuation vehicles are back across all sectors, or just proof that healthcare remains the safest haven in a still-uncertain exit environment?

Healthcare continuation vehicles have distinct advantages over tech or consumer CVs. Cash flows are more predictable, tied to reimbursement contracts rather than consumer demand. Revenue isn't discretionary — people need healthcare regardless of the economic cycle. And because most healthcare services platforms are fundamentally operational plays rather than product bets, the risk profile is narrower.

That doesn't mean they're low-risk. Regulatory exposure is high. Reimbursement rates can compress if payors push back. And integration execution is everything — buy a bunch of practices poorly and you've just created a high-overhead, low-margin mess. But compared to a SaaS platform with 90% revenue concentration in three enterprise clients or a DTC brand riding a fading trend, healthcare platforms offer a floor.

Abry Partners has been doing healthcare buyouts since the 1990s, with a focus on services, providers, and tech-enabled platforms. The firm's portfolio includes everything from behavioral health chains to revenue cycle management software to specialty pharmacy distributors.

The track record is solid but not flawless. Abry successfully exited several physician platforms over the past decade, including a gastroenterology roll-up that sold to a larger PE buyer in 2021. But the firm has also held assets longer than anticipated when exit windows closed or valuations disappointed.

The decision to pursue a continuation vehicle for Centauri rather than sell outright likely reflects a combination of conviction and pragmatism. The firm may genuinely believe Centauri has significant upside left — or it may have tested the M&A market, disliked the bids, and decided extending the hold was the better path to returning capital to LPs at an acceptable multiple.

The seven-year hold period for Centauri is longer than Abry's typical healthcare services investment, but not dramatically so. Given the disruption in exit markets over the past two years, extending another few years to capture a better valuation is a rational choice — if the underlying business supports it.

What's less clear: whether Abry will pursue an M&A exit, an IPO, or another continuation vehicle when this fund reaches the end of its lifecycle. The physician services IPO market has been functionally closed since 2022, and M&A buyers remain cautious about paying peak multiples for roll-ups with integration risk. Another CV in 2029 or 2030 isn't off the table.

With $780 million in fresh capital, Centauri will almost certainly accelerate acquisitions. The continuation vehicle gives the company a longer runway and a reset on return expectations — both of which make it easier to deploy growth capital without the pressure of an imminent exit.

Expect more dermatology and ophthalmology practices to fold into the platform over the next 18-24 months, particularly in metros where Centauri already has density. The playbook is well-established: acquire, integrate, extract synergies, repeat.

The risk is execution. Every additional practice acquired adds operational complexity. Physician retention becomes harder at scale. And if reimbursement rates compress or regulatory scrutiny increases, the margin profile can deteriorate faster than revenue grows.

But if Centauri can maintain integration discipline and avoid the operational bloat that's sunk other roll-ups, the continuation vehicle could deliver strong returns — and validate Abry's bet that the asset was worth holding.

For now, the market has spoken: $780 million says there's still money to be made in consolidating physician practices. Whether that remains true three years from now depends on execution, reimbursement trends, and whether the exit market reopens before the next fund cycle ends.

The Abry-Centauri continuation vehicle is a data point in a larger trend: private equity firms are holding healthcare assets longer and using secondary structures more creatively to manage LP liquidity without exiting.

That shift reflects both opportunity and constraint. The opportunity: healthcare services platforms still have consolidation runway in most specialties, and holding longer can capture more of that value. The constraint: exit multiples haven't recovered to 2021 levels, and neither the IPO market nor strategic M&A appetite can absorb the volume of assets that need liquidity.

Continuation vehicles solve the timing problem, but they don't eliminate the fundamental question: what's the endgame? At some point, these assets need to exit into the public markets or sell to strategics. If neither market reopens meaningfully, continuation vehicles just become a way to kick the can down the road — with diminishing returns each cycle.

For Abry and Centauri, the bet is that the next three to five years will offer a better exit window than today. Maybe they're right. Or maybe they're just the latest firm to discover that healthcare roll-ups are easier to build than to sell.